Diagnostic tests: as easy as I, II, III
Diagnostic testing keeps coming back to bite Archi, and that's not just because of my probability-based failure regarding a small relative and a missed diagnosis of congenital heart disease. No, the problem with diagnostic tests and their use and abuse remains diffi cult because the methods of research, the quality of research and the consequence of bad research aren't generally as high profi le as therapeutic failures. Perhaps we could help a bit by adopting a similar approach to evaluating diagnostic tests as we do new drugs: go for phase I, II and III studies.
Phase I diagnostic studies look at the very lowest level, not toxicity in this case but ability to separate out the grossly affected from the clearly well, for example, interleukin 8 (IL-8) levels in those with meningococcal sepsis and admissions for routine circumcision. Phase II studies work towards defi ning what the right cut-off should be for a test in a group who are more refl ective of the clinical setting we want it to be used in. Taking our example onwards, this would be the defi nition of a value of IL-8 in children with fever in an admissions unit which best defi nes those with sepsis. This is classically known as test 'derivation'. Phase III studies then go further, and test the use of clear criteria in a group with uncertain diagnosis, compared with an effective reference standard, often described as test 'validation'.
Failure to recognise the phase of test leads to real problems in clinical interpretation. For instance, a test that can tell the difference between high-functioning adults with autism and those in volunteering for a quick MRI of the head may well be useless in the community paediatrics clinic. Or may not -but there is no way of knowing with a phase I/II study. Showing that IL-6 >1000 pg/ml is almost invariably associated with gramnegative sepsis in one population of children with fever and neutropenia might mean that it's a great diagnostic test for all new admissions. But such a phase II study doesn't really prove this: it hints in the same way that radiological response of a tumour might mean that the drug is helpful, but this is not always true.
So, when you're next reading about an advance in diagnostic test technology, as well as the thoughts about prevalence, predictive values and likelihood ratios, try and peg the 'phase' fi rst and it may save you lots of time and pain.
